Legend Biotech Corporation American Depositary Shares
N/A
USD
N/A
N/A
...
Chart
Financials
Description
LEGN Company Description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
LEGN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view LEGN Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of LEGN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LEGN's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of LEGN in WallStreetBets Daily Discussion
LEGN News
Recent insights relating to LEGN
CNBC Recommendations
Recent picks made for LEGN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in LEGN
Corporate Flights
Flights by private jets registered to LEGN
Our Analysis